Clinical trials: NSCLC, Stage I
Bladder Cancer, Breast Cancer
LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer
Phase I trial to study the effectiveness of LMB-9 immunotoxin in treating patients who have advanced colon, breast, non-small cell lung, bladder, pancreatic, or ovarian cancer.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer
- Trial name
- NCT00005858
- Testing
- LMB-9 immunotoxin
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Maryland, Baltimore
Non-small Cell Lung Cancer
Evaluation of Tolerability of Adjuvant Cisplatin/Docetaxel in Completely Resected Stage IB/II Non-Small Cell Lung Cancer
The aim of this study is to evaluate the tolerability (in terms of drug delivery and toxicity) of four cycles of adjuvant docetaxel plus cisplatin in patients with completely resected stage IB-II Non-Small Cell Lung Cancer.
- Trial name
- TOLEDO (NCT00434668)
- Testing
- cisplatin/docetaxel, cisplatin/vinorelbine
- Where
- 3 sites in Belgium
- Volunteers
- 99 people
- Sponsor
- University Hospital, Antwerp
LUNG CANCER
Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC
ELIGIBILITY Non-small cell lung cancer Clinical Stage 1A (T1N0M0 a tumor that is 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, and without bronchoscopic evidence of invasion more proximal than the…
- Trial name
- NCT00188617
- Testing
- GEFITINIB
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- University Health Network, Toronto
Solid Tumor (Phase I), Ovarian Cancer
A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors.
This study is a open-label, multicenter clinical trials. The target population is participants with locally advanced or metastatic solid tumors. A total of 204 participants are planned to be included.
- Conditions
- Solid Tumor (Phase I), Ovarian Cancer, NSCLC (Advanced Non-small Cell Lung Cancer), TNBC - Triple-Negative Breast Cancer
- Trial name
- NCT07894874
- Testing
- YF550
- Volunteers
- 204 people
- Sponsor
- InventisBio Yiqi Beijing Limited
Lung Neoplasms
A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer
The purpose of this research study is to compare the effects (good and bad) on subjects and their cancer using standard chemotherapy in combination with hypofractionated proton radiation therapy.
- Trial name
- NCT01770418
- Testing
- Radiation with Concurrent Chemotherapy
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Proton Collaborative Group
Recurrent Non-small Cell Lung Cancer
INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer
This phase I trial studies the side effects and best dose of c-Met inhibitor INCB028060 and erlotinib hydrochloride when given together in treating patients with previously treated non-small cell lung cancer.
- Trial name
- NCT01911507
- Testing
- INC280, erlotinib hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- University of California, Davis
Breast Cancer, Esophageal Cancer
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells of by stopping them from dividing.
- Conditions
- Breast Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer
- Trial name
- NCT01172028
- Testing
- Taxotere (Docetaxel), Alimta (Pemetrexed)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Arizona
Lung Cancer
A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer
The purpose of Phase 1 of this study is to evaluate the safety of the combination regimen, bexarotene and ZD1839. Phase II will evaluate the median survival, time to disease progression, and toxicity.
- Trial name
- NCT00238628
- Testing
- Bexarotene, Iressa
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Stanford University
Advanced Solid Tumor, BRAF V600 Mutation
A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors
This is a Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in patients with BRAF V600-Mutant advanced…
- Trial name
- NCT05501912
- Testing
- ABM-1310
- Where
- 10 sites in China
- Volunteers
- 20 people
- Sponsor
- ABM Therapeutics Shanghai Company Limited
Lung Cancer
Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as vinorelbine, cisplatin, docetaxel, gemcitabine, and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00863512
- Testing
- cisplatin, docetaxel, gemcitabine hydrochloride
- Where
- 94 sites in United States, Australia
- Volunteers
- 34 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Locally Advanced or Metastatic Solid Tumor
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic solid tumor will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-B01D1.
- Trial name
- NCT05194982
- Testing
- BL-B01D1
- Where
- 8 sites in China
- Volunteers
- 570 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Breast Cancer, Chronic Myeloproliferative Disorders
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin by making tumor cells more sensitive to…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00036790
- Testing
- doxorubicin hydrochloride, motexafin gadolinium
- Where
- 2 sites in United States
- Sponsor
- University of Wisconsin, Madison
Early Stage Non-small Cell Lung Cancer, Non-small Cell Lung Cancer
Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR) for the Treatment of Central and Ultra-Central Early-Stage Non-Small Cell Lung Cancer
This study will evaluate the impact of CT-guided adaptive stereotactic radiotherapy (CT-STAR) to central and ultra-central early-stage non-small cell lung cancers on grade 3 or greater toxicity.
- Trial name
- NCT05785845
- Testing
- Computed tomography-guided stereotactic adaptive radiotherapy, ETHOS
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Washington University School of Medicine
Breast Cancer, Colorectal Cancer
Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Combinations of biological substances in denileukin diftitox may be able to carry cancer-killing substances directly to the cancer cells.
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
- Trial name
- NCT00128622
- Testing
- denileukin diftitox, recombinant fowlpox-CEA(6D)/TRICOM vaccine, therapeutic autologous dendritic cells
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- H. Kim Lyerly
Non-small Cell Lung Cancer
Phase I and II Study Of Stereotactic Body Radiotherapy in Medically Unresectable Patients With Stage 1 NSCLC
This clinical trial involves a radiation treatment called stereotactic radiotherapy in non-small cell lung cancer patients who have been determined to be ineligible for surgery.
- Trial name
- SBF-NSCLC (NCT00246181)
- Testing
- radiation therapy
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- Jill Deluca
Lung Cancer
CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)
Primary Objectives: To determine the feasibility, activity, and toxicity of a novel regimen using a concurrent irinotecan (CPT-11)/cisplatin and celecoxib combination for patients with unresectable NSCLC.
- Trial name
- NCT00346801
- Testing
- Celecoxib, Cisplatin, CPT-11
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)
The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of onartuzumab that can be given with erlotinib and standard chemoradiation (paclitaxel and carboplatin) to patients with NSCLC.
- Trial name
- NCT02044601
- Testing
- Onartuzumab, Erlotinib, Paclitaxel
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer
Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*02 Disease Controlled Advanced Non-small Cell Lung Cancer
The investigators previously identified a novel HLA-A*0201-restricted epitope peptide, which was derived from a cancer-testis antigen, URLC10 as a target for vaccination against lung cancer.
- Trial name
- NCT01949701
- Testing
- HLA-A*0201restricted URLC10 peptides with adjuvant
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- Shiga University
Non-small Cell Lung Cancer, First-line Treatment
Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC
This prospective, unicentric, open-labe phase I study is to evaluate the effects of autologous cytokine-induced killer cell immunotherapy combination with PD-1 inhibitor and chemotherapy in the first-line treatment of…
- Trial name
- NCT03987867
- Testing
- CIK cell, Sintilimab Injection, Pemetrexed
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Lung Cancer
Effects of Palliative Care on Quality of Life and Symptom Control in Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer That Can Be Removed by Surgery
RATIONALE: Palliative care may be more effective than standard care in improving quality of life and symptoms in patients with lung cancer.
- Trial name
- NCT00823667
- Testing
- educational intervention, medical chart review, questionnaire administration
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- City of Hope Medical Center